Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deficit Super Committee Inaction May Be Best Scenario For Biopharma

Executive Summary

It may be a best-case scenario for the biopharmaceutical industry if the Joint Select Committee on Deficit Reduction is unable to produce a proposal by Thanksgiving to cut the federal deficit by at least $1.2 trillion over 10 years.
Advertisement

Related Content

"Medicare Exchange" Proposal From Healthcare Leadership Council Could Deter Threat Of Part B Drug Payment Reductions
GPhA's New CEO Ralph Neas Brings Health Reform Advocacy Experience
GPhA's New CEO Ralph Neas Brings Health Reform Advocacy Experience
Super Committee Members Have Refrained From Drawing Lines In Sand So Far, Murray Says
GPhA's New CEO Ralph Neas Brings Health Reform Advocacy Experience

Topics

Advertisement
UsernamePublicRestriction

Register

PS053732

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel